Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Benzinga Newsdesk 3 months ago
News
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-endFavorable safety profile observed to date, with limited hematological
- Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end
- Favorable safety profile observed to date, with limited hematological toxicity
- Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need